Richard Tsai, Ph.D., is the Founder and Managing Partner of Helicase Venture. See sector focus and contact routes.
Richard Tsai, Ph.D., is the Founder and Managing Partner of Helicase Venture, an early-stage life sciences fund based in Boston that he established in 2018 after serving as a Partner and head of Life Science investments at BioEngine Capital. His investment thesis targets seed and Series A rounds in innovative life sciences and Bio-IT companies at the intersection of engineering, health, and AI, with a geographic focus spanning the United States, Austria, and China. Helicase typically leads investment rounds with initial commitments ranging from $1 million to $5 million, though historical maximum checks have reached higher amounts. Notable portfolio companies include Ribbon Biolabs, which received a $20.1 million Series A in January 2022, as well as ventures that have resulted in two IPOs and three acquisitions under the firm’s Fund I. Tsai has previously served on the boards of multiple biotech entities including Lumosa Therapeutics, Mycenax, and TOT Biopharma, reflecting deep operational involvement beyond capital allocation. While the search results do not cite specific public writing or a distinctive published point of view, his professional prof
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Boston.
Investors like Richard Tsai · Full investor directory · Investor access · Company funding database